Equillium, Inc. Annual Report: A Simple Breakdown

I’ve put together this guide to help you understand Equillium’s performance over the past year. My goal is to turn complex financial filings into clear information so you can decide if this company fits your investment goals.

1. What does this company do?

Equillium is a biotech company in the research phase. They are developing new medicines, but they do not have products on pharmacy shelves yet. Because they are still testing, they do not make money from sales. For 2023, their revenue was $0. We measure their progress by how well they move drugs through scientific testing and how much cash they have left to fund these expensive trials.

2. The Pipeline: What are they working on?

The company is focused on two main drug candidates:

• EQ504: A new treatment for severe inflammatory diseases, starting with ulcerative colitis. They are finishing safety tests and plan to ask the FDA to start human trials in mid-2026.
• EQ302: An oral pill for celiac disease and other autoimmune disorders. They are currently finishing the manufacturing and safety testing required to start human trials.

3. Financial health: "Survival mode"

Equillium is in "survival mode." In 2023, they lost about $34.5 million, mostly because they spent $23.1 million on research. By the end of 2023, they held $35.8 million in cash.

Because they have no sales, they raise money by selling more shares of stock. This gives them cash to keep working, but it also means more shares are issued, which reduces your ownership percentage. The company notes that their current cash will not cover their planned trials, meaning they will need to raise more money soon, likely by selling more stock or finding a business partner.

4. Key risks

Investing in a company like this is high-risk. Here is what you should watch:

• The "All-or-Nothing" Risk: The company’s value depends entirely on EQ504 and EQ302 succeeding. If these drugs fail their trials, the company has no other products to fall back on. You could lose your entire investment.
• Dilution: To pay for trials, the company will likely issue millions of new shares. This lowers the value of the shares you already own.
• Delisting: Equillium must keep its stock price above $1.00 to stay on the Nasdaq. If the price stays too low, they could be removed from the exchange, making it much harder to buy or sell your shares.
• Reliance on Outsiders: They hire outside companies to run their trials and make their drugs. If these partners make mistakes or miss deadlines, the company’s projects could be delayed or canceled.

5. Future outlook

The company is in a critical transition. The big milestone is starting the EQ504 human trial in mid-2026. Success there would prove the drug works and make the company more attractive to partners or investors. Until then, this remains a speculative investment. Their survival depends on managing their cash carefully and passing strict government safety tests.

Final Thought for Investors: If you are considering an investment here, ask yourself if you are comfortable with a "binary" outcome—where the company either succeeds in bringing a drug to market or runs out of cash trying. Because there is no revenue today, this is a bet on future scientific breakthroughs rather than current business performance.